ArticleFrontiers in medicine2026
Divergent risk profiles for cause-specific mortality in MASLD and MetALD: a nationwide population-based study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic-dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are overlapping but distinct conditions that influence liver disease progression and mortality. This study sought to examine how differing metabolic, behavioral, and sociodemographic profiles influence mortality in MASLD and MetALD. Methods: Adults aged 20-79 years without a history of cancer, cardiovascular disease, or viral hepatitis were selected from the Korean National Health and Nutrition Examination Surveys (2007-2015). Mortality data up to November 2023 were obtained from the National Death Registry. MASLD and MetALD were defined using the hepatic steatosis index, cardiometabolic risk factors (CMRFs), and alcohol consumption. Results: A total of 7,783 participants, weighted to represent approximately 7.6 million Korean adults, were included, with a median follow-up duration of approximately 4 years. Both MASLD and MetALD were associated with increased all-cause mortality compared to controls, with a significant increase observed in MetALD (HR 2.085; 95% CI, 1.127-3.860; Conclusion: While both MASLD and MetALD were associated with increased mortality, the contributing risk profiles differed. Alcohol-related behaviors predominated in MetALD, whereas metabolic and sociodemographic factors influenced outcomes in MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.